Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet

This randomized, double‐blind, placebo‐controlled, crossover study was the first to determine the effects of luseogliflozin in combination with a low‐carbohydrate diet (LCD) on 24‐h glucose variability, assessed by continuous glucose monitoring (CGM). A total of 18 Japanese patients with type 2 diab...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2016-07, Vol.18 (7), p.702-706
Main Authors: Nishimura, R., Omiya, H., Sugio, K., Ubukata, M., Sakai, S., Samukawa, Y.
Format: Article
Language:English
Subjects:
Administration, Oral
Blood Glucose - metabolism
Carbohydrates
continuous glucose monitoring (CGM)
Cross-Over Studies
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Diet, Carbohydrate-Restricted
Double-Blind Method
Female
Glucose monitoring
glycaemic control
Glycated Hemoglobin A - metabolism
Humans
Hypoglycemia
Hypoglycemia - chemically induced
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - pharmacology
Low carbohydrate diet
Male
Middle Aged
Nutrient deficiency
Placebos
Research Letter
Research Letters
SGLT2 inhibitor
Sodium-Glucose Transporter 2 - antagonists & inhibitors
Sorbitol - administration & dosage
Sorbitol - adverse effects
Sorbitol - analogs & derivatives
Sorbitol - pharmacology
Treatment Outcome
type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This randomized, double‐blind, placebo‐controlled, crossover study was the first to determine the effects of luseogliflozin in combination with a low‐carbohydrate diet (LCD) on 24‐h glucose variability, assessed by continuous glucose monitoring (CGM). A total of 18 Japanese patients with type 2 diabetes were randomized into two groups, in which patients first received luseogliflozin 2.5 mg once daily then placebo for 8 days each, or vice versa. Patients took luseogliflozin or placebo with a normal‐carbohydrate diet (NCD) on day 7 and with the LCD on day 8. CGM was performed on both days. Luseogliflozin significantly reduced glucose exposure in terms of the area under the curve over the course of 24 h when administered with the NCD (difference vs placebo: −555.6 mg/dl·h [1 mg/dl = 0.0556 mmol/l]; p 
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.12611